Scientists in China have developed a new intranasal flu vaccine using nano-technology that can target broad-spectrum flu viruses and induce robust immune responses.
The intranasal nano-vaccine was developed by a research group from Wuhan Institute of Virology of China announced that they have developed a new type of flu vaccine using nano-technology.
The intranasal nano-vaccine can target broad-spectrum flu viruses and induces robust immune responses, Cui Zongqiang, leader of the research group said.
"In our study, an intranasal nano-vaccine worked well against infections of H1N1 and H9N2 virus in mice," Cui said.
"The results suggest that the 3M2e-rHF nanoparticle is a promising, needle-free, intranasal administered, cross-protective influenza vaccine," he was quoted as saying by state-run Xinhua news agency.
Across China, measures have been taken to contain the winter flu outbreak.
Experts said flu infections this winter are 71 per cent above the average for the same period in the previous three years, with child cases rising sharply.